United States - English - NLM (National Library of Medicine)

hospira, inc. - dextran 40 (unii: k3r6zdh4du) (dextran 40 - unii:k3r6zdh4du) - dextran 40 10 g in 100 ml - lmd (dextran 40) is indicated for use in the adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery or other trauma. it is not indicated as a replacement for whole blood or blood components if they are available. it should not replace other forms of therapy known to be of value in the treatment of shock. lmd is also indicated for use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation. lmd is also indicated for use in prophylaxis of venous thrombosis and pulmonary embolism in patients undergoing procedures known to be associated with a high incidence of thromboembolic complications, such as hip surgery. lmd (dextran 40) is contraindicated in patients with known hypersensitivity to dextran, in those with marked hemostatic defects of all types (thrombocytopenia, hypofibrinogenemia, etc.) including those caused by drugs (heparin, warfarin, etc.), marked cardiac decompensation and in renal disease with severe oliguria or a

United States - English - NLM (National Library of Medicine)

anazaohealth corporation - dextran 75 (unii: jy83shx053) (dextran 75 - unii:jy83shx053) - dextran 75 10 mg - technetium tc99m dextran by intravenous administration is indicated as a cardiac blood pool imaging agent and as an adjunct in the diagnosis of pericardial effusion, ventricular aneurysm, or gi bleed

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - dextran 40 glucose - solution for infusion - 10/5 %w/v %w/v

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - dextran 70 glucose - solution for infusion - 6/5 %w/v

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril 10 mg - lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variet

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril 10 mg - lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed-dose combinations are not indicated for initial therapy (see dosage and administration). in using lisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (see warnings .) in considering use of lisinopril and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (see warnings ,  head and neck angioedema.) lisinopril and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treat

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a

Canada - English - Health Canada

hospira healthcare ulc - dextran; dextrose - solution - 60mg; 50mg - dextran 60mg; dextrose 50mg - replacement preparations

Canada - English - Health Canada

hospira healthcare ulc - dextran; sodium chloride - solution - 60mg; 9mg - dextran 60mg; sodium chloride 9mg - replacement preparations

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dextran 40 10%; glucose monohydrate 5% - solution for infusion - active: dextran 40 10% glucose monohydrate 5%